Gene editing, CAR-T, and cell-based regenerative medicine are moving from the lab into commercial reality. Many developers cannot build the specialized manufacturing capacity these products need on their own, so they are turning to contract development and manufacturing organizations (CDMOs). According to Grand View Research, the global advanced therapy medicinal products CDMO market was valued...